Roger Xie
Directeur Général chez Beijing Pharmasciences Co. Ltd.
Postes actifs de Roger Xie
Sociétés | Poste | Début | Fin |
---|---|---|---|
Beijing Pharmasciences Co. Ltd. | Directeur Général | 09/09/2010 | - |
UCB Research, Inc.
UCB Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, UCB Research, Inc. is a company that provides commercial physical research laboratory services. The company is based in Cambridge, MA. | Directeur Technique/Scientifique/R&D | 09/09/2010 | - |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Directeur Technique/Scientifique/R&D | 09/09/2010 | - |
Historique de carrière de Roger Xie
Anciens postes connus de Roger Xie
Sociétés | Poste | Début | Fin |
---|---|---|---|
CHINA PHARMAHUB CORP. | Fondateur | 09/09/2010 | 06/01/2011 |
Corporate Officer/Principal | 09/09/2010 | 06/01/2011 | |
China PharHub Corp. /Old/
China PharHub Corp. /Old/ Financial ConglomeratesFinance China PharmaHub Corp. ('PharmaHub') is a global pharmaceutical HUB specializing in the identification, development and marketing of pharmaceutical and healthcare products that make a significant difference to patients and society. Their corporate headquarters are located in California, with offices locations in Boston and China. In China, they have developed productive alliances and partnerships that advance their capacity to develop innovative medicines at lower costs. PharmaHub is engaged in the commercialization of promising China preclinical and clinical stage novel compounds into the global pharmaceutical markets; as well as bringing U.S. preclinical and clinical stage novel compounds into the China pharmaceutical market. | Corporate Officer/Principal | 17/08/2010 | 07/09/2010 |
GSK PLC | Corporate Officer/Principal | 01/03/2009 | 01/03/2009 |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Corporate Officer/Principal | 01/06/2008 | 01/06/2008 |
Daiamed LLC | Directeur Technique/Scientifique/R&D | 01/05/2005 | 01/05/2005 |
Formation de Roger Xie
Boston College | Doctorate Degree |
University of Science & Technology of China | Undergraduate Degree |
Statistiques
Internationale
Etats-Unis | 8 |
Chine | 3 |
Royaume-Uni | 2 |
Opérationnelle
Corporate Officer/Principal | 4 |
Chief Tech/Sci/R&D Officer | 3 |
Founder | 1 |
Sectorielle
Health Technology | 5 |
Consumer Services | 3 |
Finance | 2 |
Fonctions occupées
Actives
Inactives
Sociétés cotées
Entreprise privées
Sociétés liées
Sociétés cotées | 1 |
---|---|
GSK PLC | Health Technology |
Entreprise privées | 7 |
---|---|
China PharHub Corp. /Old/
China PharHub Corp. /Old/ Financial ConglomeratesFinance China PharmaHub Corp. ('PharmaHub') is a global pharmaceutical HUB specializing in the identification, development and marketing of pharmaceutical and healthcare products that make a significant difference to patients and society. Their corporate headquarters are located in California, with offices locations in Boston and China. In China, they have developed productive alliances and partnerships that advance their capacity to develop innovative medicines at lower costs. PharmaHub is engaged in the commercialization of promising China preclinical and clinical stage novel compounds into the global pharmaceutical markets; as well as bringing U.S. preclinical and clinical stage novel compounds into the China pharmaceutical market. | Finance |
China PharmaHub Corp.
China PharmaHub Corp. Pharmaceuticals: MajorHealth Technology China PharmaHub Corp. was a global pharmaceutical company. The firm was engaged in the identification, development, and marketing of pharmaceutical and healthcare products. The company was founded by Richard Lui, Monica Ding, and Roger Xie on July 9, 2009 and is headquartered in Diamond Bar, CA. | Health Technology |
Beijing Pharmasciences Co. Ltd. | |
Sirtris Pharmaceuticals, Inc.
Sirtris Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Sirtris Pharmaceuticals, Inc., a GSK company, is developing small molecule drugs that target the sirtuins, a family of seven enzymes associated with diseases of aging. Modulation of these enzymes offers the promise of drug discovery in multiple therapeutic areas. Sirtris was one of the pharmaceutical companies focused on the sirtuin platform and remains the innovative drug discovery. Preclinical research indicates that the sirtuins play important roles in pathways for multiple diseases of aging, including Type 2 Diabetes, as well as neurodegenerative, cardiovascular and inflammatory diseases. Sirtris researchers are working to translate this research into a potential new class of pharmaceuticals to treat diseases of aging, offering the ability for people to live longer, healthier lives. Sirtris has focused on developing many novel small molecule activators of SIRT1, the most studied member of the sirtuin family. These new chemical entities or NCEs are novel compounds that are chemically unrelated to resveratrol, a naturally occurring compound that was used as an early proof-of-concept for SIRT1 activation. Besides being structurally differentiated from resveratrol, the NCEs are more specific for the target SIRT1 and have improved drug-like properties. The company has completed several early stage translational clinical studies with the first generation NCEs and has several active clinical trials under way. Sirtris operates as an independent Discovery Performance Unit (DPU) within GSK and is located in Technology Square, Cambridge, Mass. Sirtris' culture mixes scientific curiosity with a dynamic, fast-paced environment, resembling its biotech roots while harnessing all of GSK's broad discovery, development, and commercialization capabilities. The company was founded in 2004 and is headquartered in Cambridge, MA. | Health Technology |
Daiamed LLC | |
UCB Research, Inc.
UCB Research, Inc. Miscellaneous Commercial ServicesCommercial Services Part of UCB SA, UCB Research, Inc. is a company that provides commercial physical research laboratory services. The company is based in Cambridge, MA. | Commercial Services |
Sumitomo Pharma America, Inc.
Sumitomo Pharma America, Inc. Pharmaceuticals: MajorHealth Technology Sumitomo Pharma America, Inc. operates as a biopharmaceutical company that develops pharmaceutical products. Its products include Aptiom (eslicarbazepine acetate) tablets, Latuda (lurasidone HCl) tablets, Lunesta (eszopiclone) tablets, Xopenex (levalbuterol HCl) Inhalation Solution, Xopenex HFA (levalbuterol tartrate) Inhalation Aerosol, Brovana (arformoterol tartrate) Inhalation Solution, Omnaris (ciclesonide) Nasal Spray, Alvesco (ciclesonide) Inhalation Aerosol, and Zetonna (ciclesonide) Nasal Aerosol. The company was founded in 2010 and is headquartered in Marlborough, MA. | Health Technology |